Quick Answer
Ensysce Biosciences, Inc. reported Operating Income of -$10.24 million for fiscal year 2025.
Ensysce Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$10.24M | -52.2% |
| 2024 | -$6.73M | +37.2% |
| 2023 | -$10.72M | +55.8% |
| 2022 | -$24.22M | -21.9% |
| 2021 | -$19.87M | -1131.7% |
| 2020 | -$1.61M | +51.5% |
| 2019 | -$3.33M | -247.0% |
| 2018 | -$959.2K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.74M | -680.2% | -113.7% |
| June 30, 2025 | -$1.75M | +10.5% | +11.0% |
| March 31, 2025 | -$1.97M | -6.8% | -405.2% |
| September 30, 2024 | $644.7K | +123.8% | +133.0% |
| June 30, 2024 | -$1.96M | +14.8% | -6.1% |
| March 31, 2024 | -$1.84M | +28.0% | +31.9% |
| September 30, 2023 | -$2.71M | +56.1% | -18.0% |
| June 30, 2023 | -$2.29M | +67.5% | +10.4% |
- Ensysce Biosciences, Inc. showed a decrease of -52.2% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Ensysce Biosciences, Inc.’s operating income has declined by 967.6% (from -$959.2 thousand to -$10.24 million).
- The most recent figure is from Ensysce Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: